Sugar Maple Asset Management »

Halozyme Therapeutics shares owned by Sugar Maple Asset Management

Quarter-by-quarter ownership of Halozyme Therapeutics (HALO) shares owned by Sugar Maple Asset Management from 13F filings

Historical chart of Sugar Maple Asset Management investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by Sugar Maple Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by Sugar Maple Asset Management

Quarter filed Position value Share count Share price at filing
2025-09-30 $755k 10k 73.34
2025-06-30 $744k 14k 52.02
2025-03-31 $657k 10k 63.81
2024-12-31 $373k 7.8k 47.81

More positions owned by Sugar Maple Asset Management

Abbvie (ABBV)
Spdr Gold Tr Gold Shs (GLD)
Ishares Tr TRS FLT RT BD (TFLO)
Ishares Tr Core S&p500 Etf (IVV)
Abbott Laboratories (ABT)
Ishares Tr 0-5 Yr Tips Etf (STIP)
Ishares Tr 1 3 Yr Treas Bd (SHY)
Ishares Silver Tr Ishares (SLV)
Vaneck Etf Trust Clo Etf (CLOI)
T Rowe Price Etf Cap Appreciation (TCAF)
Ishares Tr Msci Usa Min Vol (USMV)
Vanguard Specialized Funds Div App Etf (VIG)
Fidelity Covington Trust Divid Etf Risi (FDRR)
Pacer Fds Tr Swan Sos Fd Of (PSFF)
Spdr Series Trust S&p Divid Etf (SDY)

View all positions for Sugar Maple Asset Management

Top funds holding Halozyme Therapeutics

BlackRock
Vanguard Group
State Street Corporation
Arrowstreet Capital, Limited Partnership
Invesco
UBS Group
Snyder Capital Management
D. E. Shaw & Co
Geode Capital Management
Dimensional Fund Advisors
Alliancebernstein
Morgan Stanley
Macquarie Group
Federated Investors
Congress Asset Management

View all funds holding Halozyme Therapeutics